Dr. Grivas on updated findings for avelumab maintenance in bladder cancer

Petros Grivas, MD, PhD, discusses posthoc findings from the phase 3 JAVELIN Bladder 100 trial presented during the 2021 ASCO Annual Meeting. Based on the primary findings from the trial, the FDA previously approved avelumab (Bavencio) as a frontline maintenance therapy in patients with advanced urothelial cancer that has not progressed with first-line platinum-based chemotherapy.

Grivas is global co-principal investigator on the JAVELIN Bladder 100 trial and associate professor and clinical director of the Genitourinary Cancers Program at Seattle Cancer Care Alliance, and associate professor, Division of Medical Oncology, University of Washington School of Medicine.